A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

NCT06952478 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

486

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory or Relapsed Multiple Myeloma

Interventions

BIOLOGICAL: CT-P44(Daratumumab)
BIOLOGICAL: Darzalex Faspro(Daratumumab)

Sponsor

Celltrion